Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving ...

STORY: Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on Wednesday (May 7).It brings to an end a four-year stretch of steady guidance increases since the launch of its Wegovy weight ...

Novo Nordisk says it's now cutting its annual outlook - seeing sales growth, at constant exchange rates, between 13% and 21%, vs. its previous forecast of 16% to 24%, and operating profit growth ...

WW International, has formerly known as WeightWatchers, has filed for Chapter 11 bankruptcy protection in a bid to cut its debt after hugely popular obesity drugs upended its business model.

Find insight on Novo Nordisk, Siemens Healthineers, Fresenius and more in the latest Market Talks covering Health Care.